Newsroom | 4616 results

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics to Present on RNA-guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)...

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program...

LINKÖPING, Schweden--(BUSINESS WIRE)--AMRA Medical hat im Rahmen eines Gemeinschaftsprojekts, an dem auch Forscher von der University of Glasgow, der University Hospitals Cleveland und Eli Lilly and Company teilnahmen, kürzlich eine detaillierte Post-hoc-Analyse der Lilly-StudieSURPASS-3 durchgeführt. In der Analyse wurden Daten aus der Studie untersucht, um den Zusammenhang zwischen einer Tirzepatid-Behandlung und Veränderungen des Oberschenkelmuskelvolumens, des Muskelvolumen-Z-Scores sowie d...

LINKÖPING, Zweden--(BUSINESS WIRE)--AMRA Medical heeft, als onderdeel van een samenwerkingsverband van onderzoekers van de Universiteit van Glasgow, University Hospitals Cleveland en Eli Lilly and Company, onlangs een gedetailleerde post-hocanalyse uitgevoerd van Lilly's SURPASS-3-onderzoek. De analyse onderzocht gegevens uit de studie om het verband te bepalen tussen behandeling met tirzepatide en veranderingen in het dijbeenspiervolume, de z-score van het spiervolume en de vetinfiltratie in d...

LINKÖPING, Suecia--(BUSINESS WIRE)--AMRA Medical, en colaboración con investigadores de la Universidad de Glasgow, University Hospitals de Cleveland y Eli Lilly y compañía, realizó recientemente un análisis post hoc detallado del ensayo SURPASS-3 de Lilly. Este análisis exploró los datos del ensayo para determinar la asociación entre el tratamiento con tirzepatida y los cambios en el volumen muscular, la puntuación z de volumen muscular y la infiltración adiposa muscular del muslo en personas c...

LINKÖPING, Suède--(BUSINESS WIRE)--AMRA Medical, dans le cadre d’un effort collaboratif composé de chercheurs de l'Université de Glasgow, des University Hospitals Cleveland et d'Eli Lilly and Company, a récemment réalisé une analyse post-hoc détaillée de l'essai SURPASS-3 de Lilly. L'analyse explore les données de l'essai pour déterminer l'association du traitement par tirzépatide avec les changements du volume musculaire de la cuisse, des scores z du volume musculaire et de l'infiltration de g...

LINKÖPING, Svezia--(BUSINESS WIRE)--AMRA Medical, nell'ambito di uno sforzo collaborativo da parte di ricercatori dell'Università di Glasgow, degli ospedali universitari di Cleveland e di Eli Lilly and Company, ha di recente condotto un'analisi dettagliata post-hoc dello studio clinico di Lilly SURPASS-3. L'analisi ha esplorato i dati ottenuti dallo studio clinico per individuare il legame tra il trattamento con tirzepatide e le modifiche nel volume muscolare delle cosce, sul punteggio z del vo...

LINKÖPING, Sweden--(BUSINESS WIRE)--New research unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price...

MONTREAL--(BUSINESS WIRE)--Innovaccer, the leading healthcare AI company, today announced that its recently acquired actuarial science company - Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada. The research offers new insights into the characteristics of Medicare patients initiati...